Welcome to our dedicated page for CME GROUP SEC filings (Ticker: CME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CME GROUP's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CME GROUP's regulatory disclosures and financial reporting.
CME Group Inc. announced a planned leadership transition in which longtime Chairman and CEO Terrence A. Duffy will become Executive Chairman and President and CFO Lynne C. Fitzpatrick will become Chief Executive Officer. The change will take effect on the later of March 1, 2027 and the filing of CME’s 2026 Form 10-K.
Duffy will remain CEO until that transition date, then serve as Executive Chairman through December 31, 2027 under a transition agreement that generally preserves his current pay and benefits while modifying certain equity and bonus terms. Fitzpatrick will continue as President and CFO until the transition and will join the Board and its Executive Committee when she becomes CEO.
Under her new employment agreement, Fitzpatrick will receive a $1.2 million base salary, with an annual bonus target of 200% of salary and a long-term incentive target of 700% of salary, plus defined severance, equity-vesting and post-employment non-compete terms.
CME Group Inc. reported final voting results from its reconvened 2026 Annual Meeting of Shareholders. Proposals to eliminate the rights of Class B-1 and Class B-2 shareholders to elect their own directors did not pass, despite strong support from the combined Class A and B shares. A related amendment to the certificate of incorporation received majority approval but will not be filed because it was contingent on those governance changes and a Class B-3 proposal, which did not achieve quorum. All Class B-1 and Class B-2 directors standing for election were re-elected to serve until the 2027 annual meeting, while Class B-3 director Elizabeth A. Cook will continue as a holdover director until her successor is elected or she resigns.
CME Group Inc. senior managing director and Chief HR Officer Hilda Harris Piell reported an open-market sale of 5,753 shares of Class A common stock at an average price of $304.63 per share. Following this transaction, she directly holds 27,702 shares of CME Group stock.
CME Group Inc. held its 2026 annual meeting of shareholders on May 14, 2026, and reported the voting results. Shareholders representing 318,466,544 shares, or 87.78% of the 362,808,081 Class A and Class B shares outstanding as of March 16, 2026, were present in person or by proxy. Class B-1, B-2, B-3 and B-4 did not reach their required 33.3% quorum, so the proposals under Items 4 through 8 were adjourned to a virtual meeting on June 9, 2026. Equity director nominees were elected with strong majorities, and shareholders ratified Ernst & Young LLP as independent auditor for 2026. On an advisory basis, shareholders also approved compensation for the company’s named executive officers.
CME affiliate filed a Form 144 proposing the sale of Common shares.
The filing lists multiple lots of issuer‑granted securities described as Restricted Stock and Performance Shares with grant dates from 09/14/2020 through 03/15/2025. The record shows lot sizes such as 512 shares (09/14/2020) and 2,015 shares (03/15/2025) and a filing date of 05/18/2026.
CME Group Inc. Chairman and CEO Terrence A. Duffy reported selling a total of 35,000 shares of Class A common stock in open-market transactions on May 15, 2026. The sales occurred in two blocks: 9,004 shares at a weighted average price of $299.58 per share and 25,996 shares at a weighted average price of $298.14 per share.
According to the footnotes, each reported price is a weighted average for multiple trades, with actual sale prices ranging from $298.00 to $298.89 for one block and $299.00 to $299.95 for the other. The filing indicates these were standard open-market sales of non-derivative common stock.
CME Group Inc ownership filing: Vanguard Capital Management reports beneficial ownership of 27,044,709 shares of Common Stock, equal to 7.45% of the class as reported for the period ending 03/31/2026.
The filing states Vanguard has sole dispositive power over 27,044,709 shares and sole voting power for 3,677,427 shares. The filing describes holdings held on behalf of various Vanguard affiliates and funds. Signature on the filing is dated 04/29/2026.
CME Group Inc., through its subsidiary Chicago Mercantile Exchange Inc., entered into Amendment No. 11 to its 364-day multi-currency credit facility with a syndicate of banks led by Bank of America and Citibank. The amended facility provides a $7 billion multi-currency revolving secured credit line, which is eligible to be increased to $10 billion. It is intended to provide temporary liquidity if a clearing firm or depositary fails to meet obligations, or if there is a disruption in the domestic payments system affecting settlements between CME and its clearing firms. Cash and U.S. Treasury guaranty fund contributions, along with performance bond assets under the CME rulebook, may be used as collateral, and CME must comply with a consolidated tangible net worth test.
CME Group Inc. reported strong first-quarter 2026 results with higher trading activity and earnings. Total revenues rose to $1,880.1 million, up 14% from $1,642.3 million a year earlier, driven mainly by clearing and transaction fees of $1,542.6 million, up 15%.
Operating expenses increased 7% to $570.4 million, but operating income still climbed to $1,309.7 million from $1,108.0 million, lifting the operating margin to 69.7%. Net income grew to $1,154.3 million, up 21%, and diluted earnings per share improved to $3.18 from $2.62.
Higher investment income from performance bond and guaranty fund balances contributed to non‑operating income of $201.2 million. CME continued returning capital, paying common dividends of about $2,702.9 million and repurchasing 1.84 million Class A shares for roughly $538.7 million under its $3.0 billion buyback authorization.